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INTRODUCTION
Leukemia is the term used for haematopoietic neoplasm, presenting with wide spread 
involvement of bone marrow and peripheral blood by blasts and is the most common cancerous 
disorder in children1. 
Virchow recognized  leukemia  as  a  distinct  disease  in  1845  when  he  used  the  term 
weisses blut  to describe the findings in an autopsy in which the ratio of red corpuscles to 
“colorless (in mass white)” was reversed2.  He used the term leukemia for the first time in 1847 
and subsequently, described lymphatic and splenic forms3. 
           Friedreich recognized acute and chronic types in 1857. 
            Neumann, in 1868, identified the bone marrow as the origin of leukemia and used 
myelogenous as a provisional term that has been validated over time.
             The first case of Acute Myeloid Leukemia (AML) was originally termed acute non 
lymphocytic leukemia in 1900. 
During the first half of the century most of the subcategories of myeloid leukemia were 
identified by light  microscopy with the aid of cytohistochemical  stains and were described 
based  on  the  resemblance  to  normal  hematopoietic  precursors.  The  recognition  of  the 
Philadelphia chromosome in chronic myeloid leukemia (CML) by Norwell and Hungerford in 
1960 was the first demonstration of recurring chromosomal abnormality in leukemia. 
In 1976 FAB classification was proposed, with several subsequent modifications. The 
FAB group defines seven subsets of AML. Four based on the percentage of maturing cells and 
three based on lineage.FAB classifies acute lymphoblastic leukemia (ALL) into three types 
based on morphology as L1, L2, and L3.
In  the  latter  half  of  the  last  century,  numerous  cytogenetic  abnormalities,  including 
specific  translocations,  were  identified  in  subtypes  of  AML  and  led  to  changes  in 
classifications, as proposed in 1997 by the WHO4. 
Cytogenetics has profound effect on prognosis and treatment.
The WHO subdivides AML into true denovo AML occurring predominantly in young to 
middle-aged adults, with recurring cytogenetic translocations or inversions and MDS related 
AML occurring in elderly adults often with complex chromosomal abnormalities The WHO 
recognizes therapy related AML and retains the morphologic subcategories of the FAB in cases 
not otherwise classified. The category of acute leukemia of ambiguous lineage is also added.
   As  per  WHO  classification  (2001)  the  ALLs  are  separated  under  three  broader 
categories,  precursor  T-cell,  precursor  B-cell,  and mature  B-cell  neoplasm based  on   their 
Immunophenotype5. 
The high cost of cytogenetics and Immunophenotypic studies stands in way of routine 
application in all patients.
           Inspite of advances made in classification and prognostic factor delineation, it is 
essential  to  classify  leukemias  basically  into AML and ALL as they differ  significantly  in 
management and prognosis. This can very well be done by combination of morphology and 
cytochemistry which has a sensitivity of more than 92%6. In a developing country like India all 
the patients do not have accessibility to cytogenetics and Immunophenotypic studies. Hence 
classification  was  hitherto  done  by  morphology  alone  in  the  past  decades.  This  situation 
necessitated the introduction of cytochemistry,  which is  an improvement over the previous 
method, though not up to the level  of precision obtained in cytogenetic studies.  Hence the 
present study has been taken up to subtype leukemias using morphology and cytochemistry.
  
AIM OF THE STUDY
 To evaluate the clinical and haematological profile of patients with leukemia admitted to 
Government Rajaji Hospital, Madurai.
 To classify leukemia based on morphology.
 To employ cytochemistry for precise subtyping.
 To evaluate the correlation between morphology and cytochemistry.
 To employ immunophenotyping in selected cases.
REVIEW OF LITERATURE
Blood contains several types of cell each having a distinct appearance and function. The 
process  of  production  of  various  cells  from  the  haematopoietic  stem  cell  is  known  as 
haematopoiesis.  During the early  embryonic period haematopoiesis  occur  in the embryonic 
yolk sac, then during development it shifts to the liver, spleen and then ultimately to the bone 
marrow which becomes the important site of blood cell production. 
NORMAL HAEMATOPOIESIS  
THE ERYTHROID SERIES
                     The pro-erythroblast is the least mature of the erythroid series; it undergoes rapid 
division and gives rise to basophilic erythroblasts. Next stage is the polychromatic erythroblast; 
the characteristic polychromatic appearance of the cytoplasm is derived from the mixture of the 
basophilic ribonucleic acid (RNA) and acidophilic hemoglobin.  Proliferative activity ceases 
after this stage. Next stage in development is the orthochromatic erythroblast which has a small 
pyknotic nucleus. It develops into the mature erythrocyte. 
THE GRANULOCYTIC SERIES
                  The myeloblast is the morphologically identifiable earliest precursor of myeloid 
series.  There  are  no  typical  granules  in  the  moderately  basophilic  cytoplasm.  Nuclear 
chromatin  is  fine  with  typically  prominent  two  to  three  nucleoli,  there  may  be  up  to  six 
nucleoli.  It  develops  into a  promyelocyte,  it  has  some cytoplasmic granules  and a  slightly 
coarser  appearing  chromatin,  nucleoli  are  still  present.The  myelocyte  is  the  next  stage. 
Granulocyte precursors undergo active proliferation upto the myelocyte stage.        
               Subsequent steps in the maturation process, involve progressive changes in the 
conformation of the nucleus from round in the myelocyte through Metamyelocyte, stab and the 
segmented in the mature form.
THE LYMPHOID SERIES
Lymphoblasts are slightly smaller, the ratio of the nucleus to that of the cell is greater, 
and the number of nucleoli per nucleus tends to be fewer. Differentiation into mature forms 
does not proceed along such morphologically well-demarcated steps as with the other blood 
cell  series,  and  the  morphological  features  largely  reflect  whether  the  cell  is  engaged  in 
proliferative activity or is in the dormant state.                          
ACUTE LEUKEMIA DEFINITION
Acute leukemias are the result of accumulation of early myeloid or lymphoid precursors 
in the bone marrow, blood and other tissues and are thought to arise by somatic mutation of a 
single cell within a minor population of stem or early progenitor cells in the bone marrow or 
thymus. As per WHO classification a blast count of above 20% is sufficient for the diagnosis of 
acute leukemia as against 30% blasts prescribed earlier7.
EPIDEMIOLOGY        
The overall age adjusted incidence of leukemia varies from 0.34% to 1%8.
ALL is the most common paediatric malignancy accounting for three-fourth of all newly 
diagnosed leukemias and one-fourth of all cancers in childhood. It constitutes about 62.5 to 
75% of cases in children9. 
The most common age group at presentations for ALL is 2 to 6 years10. 
In contrast to ALL, the incidence of AML is quite constant from birth throughout the 
first 10 years. Following a slight peak in adolescence the incidence remains nearly constant 
upto 55 years of age, after which it increases progressively. The case ratio of ALL to AML in 
children under 15 years is 4:1 approximately the reverse of the ratio in adults11. 
             In children ALL, L1 constituted about 63.3%, L2- 36.3%11. While other reviews quote 
L1 being about 80 to 85%, L 2 -15% and L3 –1.2%12. ALL L2 blasts were more common in 
adults and L1 blasts were more common in children. In adults L1 forms 21% and L2 68% of 
cases13.
Among AML, M2 is the most common (27 – 29%) followed by M4 (16 – 25%) and then 
M5 (13 – 22%)14.
Male preponderance is a salient feature of childhood tumors11.
In infants AML M4, M5 is more common15. Where as other reviews quote ALL to be 
common16. 
ETIOLOGY
The causes for ALL in adults are largely unknown. Atomic nuclear fallout17 and high 
level of benzene exposure are accepted as causes for ALL18. 
As far as AML is concerned environmental, occupational and genetic factors play a role 
in pathogenesis.
 Individuals  with  genetic  disease  that  promote  genomic  instability  such  as  Bloom’s 
syndrome, Fanconi anemia, and Ataxia Telangiectasia are at increased risk for development of 
acute  leukemia19.  In  addition,  both  Down’s  syndrome  and  Neurofibromatosis  Type  I20 are 
associated with an increased incidence of childhood leukemias. 
The  ratio  of  ALL  to  AML  in  children  with  Down’s  syndrome  follows  the  usual 
childhood distribution except during the first three years of life when AML (FAB M 7) is more 
likely to occur than ALL21.   
Infantile monosomy 7 syndrome can evolve into aplastic anaemia.
Fanconi anaemia confers the highest risk for developing AML. 
          Incidence of leukemia has been increasingly reported in workers involved in shoe 
making, organic synthesis and  rubber and paint manufacturing.
Ionizing radiation is also implicated in the etiology of leukemia. An emerging set of 
observations indicates that intensive chemotherapy can induce second lymphoid or myeloid 
malignancies22.
Drugs have also been linked to AML, with the most convincing evidence pertaining to 
the antineoplastic agents, particularly alkylating agents and topoisomerase II inhibitors. The 
time interval between onset of leukemia and exposure to alkylating agent ranges from 1 to 28 
years and is most commonly in the range of 5 to 9 years23.
PATHOBIOLOGY
           Leukemia is  associated with changes in chromosome number,  translocation and 
inversions of genetic material. These alterations result in activation or increased transcription of 
oncogenes.
In  case  of  lymphoid  neoplasms  many  of  the  oncogenic  rearrangements  stem  from 
mistakes  during  events  that  occur  during  antigen  receptor  gene  expression.  B  and  T  cell 
progenitors express a V ( D) J recombinase activity that cuts DNA at specific sequences within 
the  immunoglobulin  and T cell  receptor  loci  and many pathogenic  rearrangements  seen in 
lymphoid neoplasm are caused by inappropriate joining of these sites to sequences flanking 
proto oncogenes.
The most common cytogenetic abnormality in ALL in adults is the abl bcr fusion gene. 
Other gene rearrangements result in loss or gain of function mutations involving transcription 
factors that are involved in normal haematopoeisis.
In AML loss or inactivation of tumor suppressor gene is implicated which have key 
regulatory function in controlling cell cycle progression. There is evidence of two hit model of 
leukemogenesis.  Fusion  genes  (AML  1/ETO,  CBF/SMMHC)  and  PML/RAR  ALPHA 
(promyelocytic leukemia/ retinoic receptor) involved in  specific chromosomal abnormalities. t 
( 8;21,), inv 16 and t (15;17) impair differentiation and apoptosis, whereas other classes of 
genetic changes such as mutations in flt 3 and nRAS promotes proliferation. Topoisomerase II 
inhibitor administration is associated with AMOL with 11q 23 and 21q 22 translocation.
   
SOME KEY CLINICAL FEATURES
AML and ALL differ in clinical presentation response to the   chemotherapy and course.
Fatigue and lethargy correlate with the degree of anemia, 
DIC is commonly associated with APL.
Petechia and ecchymoses are the most common manifestations of hemorrhage at the 
time of diagnosis in 40% to 60% of patients with acute leukemia24,25. 
        In a large series of patients with acute leukemia, leukemia cutis occurred in 11% of the 
patients  with  AML  and  in  1.3%  of  patients  with  ALL,  and  retinal  bleeding  occurs  in 
approximately 15 % of patients in acute leukemia at diagnosis.
Skin  involvement  is  rare  in  ALL.  When  it  occurs  it  is  associated  with  pre  B  cell 
phenotype26. 
Clinical features of AML M5 are cutaneous lesions, gum infiltration, and CNS disease. 
CNS involvement has been reported in 3 to 22% of patients and is more common in acute 
monocytic leukemia than in other subtypes of AML27.
CNS involvement by leukemia occurs in 2% of patients and is manifested by headaches 
vomiting and cranial nerve palsy28. Ferry JA etal had noted that testicular involvement is less 
common in AML than in ALL29.
One third of  patients  with ALL have bleeding symptoms at  diagnosis  which is  less 
frequent than in patients presenting with AML.
Generalised lymphadenopathy occurs in 50% of ALL cases and in insignificant number 
of AML cases30. 
Gum hypertrophy  is  present  in  3-5% of  acute  leukemia  cases  of  which  88.9% are 
AML31. 
Myeloid sarcoma or  Myeloblastoma is an   extra medullary tumor that occurs in 2-14% 
of cases of AML, common sites being the orbit and para nasal sinuses 
LAB INVESTIGATIONS
Patients should have a battery of diagnostic laboratory test to confirm the diagnosis, 
subcategorize  for  prognostic  classification  and  plan  for  appropriate  therapy.  These  include 
complete blood count with examination of peripheral blood smear, electrolyte measurements, 
creatinine, hepatic enzymes, uric acid, calcium, albumin levels, chest radiography, CT, lumbar 
puncture, bone marrow aspiration and biopsy.  
There  is  elevation  of  serum  uric  acid  levels  although  gout  is  a  rare 
complication.Hyperphosphatemia and hypocalcemia can occur.
Serum lactate dehydrogenase is elevated.
Coagulation parameters are normal and disseminated intra vascular coagulation is rare.
  The Revised criteria for CNS involvement at diagnosis, As quoted by Mastrangelo R32 is 
as follows -
CNS-1 - one blast cell 
CNS-2 - <5 WBC/micro litre with blasts cells
CNS-3 -> 5 WBC/micro litre with blasts or Cranial nerve involvement.   
PERIPHERAL SMEAR AND BONE MARROW
Despite  the  advent  of  modern  ancillary  techniques,  morphologic  examination  and 
cytochemical  staining of  well-prepared air-dried peripheral  blood smears  and bone marrow 
smears are critical in the pathologic diagnosis and classification of acute leukemias. Anaemia is 
more common in AML and is predominantly normocytic and normochromic. Nucleated red 
cells  are  more  common in  AML.  Alternatively  ALL may  present  with  leukoerythroblastic 
picture.  Adult  patients  with ALL have normal  or  only moderately elevated WBC count at 
diagnosis.  15 % of  patients  present  with marked hyper  leukocytosis.  One third  of  patients 
present with platelet count less than 25000 x 106/litre33. 
Subleukemic presentation is seen in 21.90% of cases34. 
MORPHOLOGICAL FEATURES OF LYMPHOBLAST
Cytologic 
features
L1 L2 L3
Cell size Small cells 
predominate
Large, heterogeneous in 
size
Large and 
homogeneous
Amount of 
Cytoplasm
Scant Variable, often mod. 
Abundant
Moderately 
abundant
Nucleoli Not visible, or small 
and inconspicuous
One or more present, 
often large
One or more 
present often 
prominent
Nuclear 
Chromatin
Homogeneous in any 
one case
Variable, heterogeneous 
in any one case
Finely stippled 
and 
homogeneous 
Nuclear Shape Regular, occasional 
clefting or indentation
Irregular, clefting and 
indentation
Regular oval to 
round
Basophilia of 
cytoplasm
Variable Variable Intensely 
basophilic
Cytoplasmic 
vacuolation
Variable Variable Prominent
SCORING SYSTEM TO DISTINGUISH L1 from L2
Features Description Scoring
Nuclear/Cytoplasmic ratio
Nucleoli
Nuclear membrane
Cell Size
>20% of cell area  is 
cytoplasm in  >25% of cell
<20% of cell area   is 
cytoplasm in >75% of cell
One or more prominent 
nucleoli in <25% of cell
Absent or inconspicuous in 
>75% of cell 
Irregular in >25% of cells
>50% of large cells 
L>2xdiameter of 
lymphocytes.
-1 (favors L2)
+1 (favors L1)
-1
+1
-1
-2
Occasionally  the  morphologic  distinction  between  L1/L2  and  L3  may  be  obscured 
because L1/L2 blasts may sometimes show significant cytoplasm vacuoles.
 Granular variant of ALL shows presence of granules in some of the blasts; these are 
negative  for  MPO and faintly  positive  for  PAS and Sudan black.  Another  study found no 
prognostic  difference  for  this  granular  variant  of  ALL .  The  granules  are  larger  and  less 
abundant than in AML.
Azurophilic granules are observed in 10% of L1 and L2 blasts, they may be confused 
with  myeloblasts  and  reliable  differentiation  requires  cytochemical  stains  and 
immunophenotyping
Myeloblasts are grouped into 3 types of blast cells. All have central nuclei with fine 
uncondensed chromatin and prominent nucleoli. Type I blasts do not have cytoplasmic granules 
but type II blasts have small number of primary granules. Type III blasts are similar to Type II 
blasts with the exception of more abundant azurophilic granles.
CYTOCHEMISTRY
Cytochemistry is the study of chemical elements found in cells. These elements may be 
enzymatic such as peroxidases or nonenzymatic such as lipids and glycogen.
The principal uses of cytochemistry are
• To characterize blast cells in acute leukemia as myeloid.
• To identify granulocytic and monocytic components of AML.
• To  identify  unusual  lineages  occasionally  involved  in  clonal  myeloid  disorders 
(basophils and mast cells).
• To detect cytoplasmic abnormalities and enzyme deficiencies in myeloid disorders such 
as MPO deficient neutrophils in MDS and acute leukemia.
               As per Hayhoe, cytochemistry is particularly useful for the characterization of 
immature cells, when they are performed on peripheral blood films, bone marrow aspirates and 
touch preparations from lymph node35.
 Cytochemical results were confirmed by ultrastructural studies in 90% of the cases. 
Clinically  significant  discrepancies  between cytochemical  and  ultrastructural  interpretations 
were rarely found36. 
Elghetany MT, et al in their study had found that, some cases of M1, M5a, M7, and L2 
were morphologically similar37. In such cases, cytochemical stains can provide an inexpensive 
and readily available diagnostic tool 
Gassmann in 1997evaluated the morphological findings in 150 consecutive cases of T-
lineage acute lymphocytic leukaemia (T-ALL). Cytochemistry including PAS staining and acid 
phosphatase reaction were proved to be of limited value for the diagnosis of ALL38.
Sharma JS and Mohindroo S had found that the concordance with morphology alone 
was 75% which improved to 92% when cytochemistry is included6. 
The  cytochemical  profile  of  blasts  is  in  concordance  with  immunophenotype, 
particularly in more differentiated AML subtypes, M3, M4 and M539.
The stains commonly used are 
1) Myeloperoxidase (MPO)
2) Sudan Black B (SBB)
3) Non specific esterase (NSE)
Alpha napthyl acetate esterase
Alpha napthyl butyrate esterase
4) Specific esterase
5) PAS 
MYELOPEROXIDASE 
Bainton  D  had  found  that  Myeloperxidase  (MPO)  is  located  in  the  primary  and 
secondary  granules  of  granulocytes  and  their  precursors,  and  in  specific  granules  of 
eosinophil40. It is also present in basophil granules. Reaction is weakly positive in monocytes. 
MPO splits hydrogen peroxide, and in the presence of a chromogenic electron donor 
forms an insoluble reaction product. Various benzidine substitutes are used of which 3, 3’-
Diaminobenzidine  (DAB)  is  the  preferred  chromogen.  The  reaction  product  is  some  what 
stable, insoluble and nondiffusible41. 
Alternate nonbenzidine based techniques employ 4 chloro-1 naphthol. It gives very crisp 
staining, but is soluble in some mounting media and immersion oil42.
 3-amino 9 ethyl carbazole is also employed; it shows some diffusibility and does not 
stain as strongly as DAB43.
ChesonBD etal , had concluded that Lymphocytes and erythroid precursors are negative 
and demonstration of MPO activity in leukemic blasts establishes a diagnosis  of AML.and 
added that in cases of ALL residual normal MPO- positive immature precursors are present in 
small numbers44.
Glick AD et al   reported MPO positivity in 19 of 83 B cell ALL, 16 of these cases had 
MPO positive blasts of more than 10%45. Mckenna reported MPO positivity in 20 out of 150 
cases of T cell ALL. Most of the cases showed weak positivity in the range of 5% but one case 
showed 20% MPO positivity46. The sensitivity and specificity of MPO stain is 69% and 100% 
respectively47.  
At the Anderson cancer center, cases of ALL with 20% to 60% MPO positivity in the 
blast population with absence of myeloid markers are reported. All cases were typical pre B 
cell ALL with expression of CD19, CD 10, CD34, and TdT.
SUDAN BLACK B 
Sheehan H and Storey G proposed an improved method of staining neutrophil granules 
with Sudan black B stain, they proposed that SBB stain the granule membranes, the pattern 
closely resembling that of MPO but SBB positivity is stronger than MPO48.
Lillie R and Burtner H had proposed that  the sudanophilia  of neutrophil  granules is 
stable in relation to peroxidases .The reaction product is black and granular49.
The SBB  is non specific in diagnosing AML, as some ALL (especially the granular 
ALL) may have a weak SBB positivity. Lymphoblasts show a nongranular smudgy positivity50.
Monocytes may contain sudanophilic granules and monocytic leukemia may be SBB 
positive, Erythroid precursors and lymphoblasts are negative. 
PAS
PAS is present in many normal blood cells. The reaction product is red, with intensity 
ranging from pink to bright red. Cytoplasmic positivity may be diffuse or granular51.  
Most cases of ALL have a characteristic “block” PAS staining pattern. This Staining 
pattern distinguishes ALL blasts from  other cell types (such as granulocytes, megakaryocytes, 
and monocytes) that can have diffuse cytoplasmic PAS staining. 
The finding of block PAS positivity is not specific for ALL, and block PAS reactivity 
can be seen in some acute myelogenous leukemia such as acute erythroblastic leukemia52.        
   As per J S Lilleyman etal, the PAS reaction features in ALL is strongly associated with a 
poor prognosis.
PAS  staining  do  not  distinguish  myeloid,  T-,  B-,  or  non-T/non-B  cell  lines. 
Characteristic reaction (large number of coarse granules against a clear background forming a 
ring around the nucleus) is found in erythroblastic leukaemia cell line and along myeloid series 
its intensity increased in more mature cells.
Snower DP etal, in their study of 51 cases found that the  sensitivity and specificity of 
the PAS stain alone for lymphoblastic leukemia was 52% (15 true positives of 29) and 81% 
(four false positives), respectively53. The sensitivity of a cytochemical-staining combination of 
PAS positivity  and myeloperoxidase,  Sudan black  B,  and  alpha-naphthyl  butyrate  esterase 
negativity  in  defining  cases  of  lymphoblastic  leukemia  remained  at  52%;  however,  the 
specificity  of  this  combination  for  lymphoblastic  leukemia  was  100% (no false  positives). 
Thus, a positive PAS stain, in combination with negative myeloperoxidase, Sudan black B, and 
alpha-naphthyl butyrate esterase stains, continues to have a diagnostic role in the distinction 
between  lymphoblastic  and  myeloblastic  leukemia,  and  greater  immunologic  sophistication 
serves to support this position.
ESTERASES
Leukocyte esterases are a group of enzymes that hydrolyse acyl or chloroacyl esters of 
alpha napthol AS. 
9 esterase isoenzymes are present which fall into 2 groups in gels. Bands 1, 2, 7, 8 and 9 
correspond to specific esterase of granulocytes,  they stain specifically with Naphthol AS-D 
Chloroacetate esterase. Bands 3, 4, 5 and 6 correspond to non-specific esterase, they stain with 
Alpha –Naphthyl acetate esterase and Alpha –Naphthyl butyrate esterase.
Moloney  W  had  demonstrated  esterase  activity  in  monocytes  using  naphthol  ASD 
chloroacetate54.
            Yam L etal had described that the most commonly used substrates to demonstate NSE 
activity are napthyl butyrate and alpha napthyl acetate, the reactivity of which in monocytes is 
granular or diffuse depending on the color developer used55.
            Li  C  etal  had  described  that,  monocytic  NSE  is  inhibited  by  Na  F,     In 
megakaryoblasts, the NSE activity is partially resistant to NaF inhibition, megakaryoblasts are 
negative with ANB staining. Lymphoblast may be positive for NSE, with variable inhibition by 
NaF56.        
   Nonspecific esterase, and chloroacetate esterase reaction are found in myelocytic and 
monocytic cell lines with the reaction intensity increasing progressively in more mature cells.
   NSE stains are useful in differentiating M2 from M4. 
 
ACID PHOSPHATASE
Cytochemically demonstrable Acid phosphatase (AP) is ubiquitous in haematopoietic 
cells.  Focal  acid  phosphatase  reaction  is  found  in  all  T-ALL  cell  lines,  whereas 
myeloid/monocytoid  lines  have  semicircular  distribution  and B-cell  lines  have  cytoplasmic 
distribution of activity. Acid phosphatase activity appeared to decline with maturation along 
both myeloid and T-cell lineage. Its main diagnostic use is in the diagnosis of T cell acute 
leukemia and Hairy cell leukemia57. But these are more reliably diagnosed and characterized by 
immunophenotyping when this is available.
IMMUNOPHENOTYPING
The development of monoclonal antibody against cell surface markers of blood cells and 
their conjugation with certain flurochromes markedly contributed to the application of flow 
cytometry in the study of normal haematopoiesis. 
Commitment  to  B  cell  differentiation  is  indicated  by  the  appearance  of  CD19  & 
CD10.Typical  phenotype  of  peripheral  B  lymphocyte  is  CD19+,  CD20+,  CD21+  and 
CD22+.Majority of blood T lymphocytes are CD2+, CD3+ and CD7+ and express either CD4 
or CD8.
CD33 is the earliest marker for myeloid differentiation. Immature myeloid cells become 
CD13+ followed  by  appearance  of  CD15 and  CD11b.  in  contrast  monocytes  are  strongly 
CD33+ and weakly CD15 and CD4 positive.
IMMUNOPHENOTYPING IN HEMATOLOGICAL MALIGNANCY
Markers  specific  for  hematological  malignancy  exist  only  when  a  new  protein  is 
encountered encoded by a  gene resulting from fusion of  two normal  genes.  E.g.  (bcr-abl). 
Diagnosis by immunophenotyping can be still accurately made by routine leukocyte antigen 
and other proteins which are expressed on cell surface. It is based on 
1) Presence of marker in amount significantly more than normal.
2) Aberrant phenotype resulting 
a) Expression of marker from lineage on which it is not normally expressed.
b) Asynchronous antigen expression.
The immunologic relevance of the immunophenotype to the FAB subtypes M1, M2, M4, 
and M5 was possible in greater than 80% of cases. Immunophenotyping is to be done at least in 
cases with negative or inconclusive cytochemistry and has suggested that the best method for 
typing acute leukemia is by a study using a combination of morphology, cytochemistry and 
immunophenotyping. 
CD10 expression is lower in infants and in children. 
In the study on lineage promiscuity in leukemia, CD7 which is the most sensitive marker 
of T cell ALL is found in 20% of AML cases. 
Bucheri  V  etal    had  proposed  a  scoring  system  for  a  diagnosis  of  biphenotypic 
leukemia58. 
Points B cell T cell Myeloid
2 CD79a ,CD 22
cytoplasmic IgM
CD3 MPO
1 CD 19 ,CD10 CD2 CD5 CD33 CD13
0.5 TdT TdT ,CD7 CD14 ,CD15,
CD11c,CD11b
Biphenotypic acute leukemia is established when score from two separate lineages is 
more than 2. Recent studies include CD117 as a highly specific myeloid marker equivalent to 2 
points and T cell receptor a highly specific T cell marker with 2 points.
 Expressions of myeloid antigen marker are slightly more frequent in B-lineage ALL 
than in T-lineage ALL but have no prognostic value59.
For therapeutic purposes one need only to distinguish T cell & mature B cell cases from 
those originating from precursor B cell.
It is concluded that morphology, histochemistry and immunological phenotype on bone 
marrow smears are the main diagnostic basis for AML-M 0. The use of multiple monoclonal 
antibodies for staining may improve the accuracy as CD3/CD13 were positive, and CD2/CD3/
CD10/CD19/CD22 were negative in AML M0.
A small  subset  of  mature  B cell  ALL with surface  immunoglobulin  expression  and 
chromosomal translocation t (8;14) are shown to express TdT.
 Mature B-cell ALL is characterized by expression of surface immunoglobulin, either 
kappa or lambda, in addition to other markers common to B-lineage ALL, including CD10, 
CD19, CD20, and CD22.
Bucheri V. etal had observed that precursor B cells typically have TdT reactivity and 
coexpression of CD10, CD19 and absence of surface immunoglobulin expression. They also 
observed that some cases with earliest precursor immunophenotype may express TdT and HLA 
DR only with no T cell  or myeloid associated markers these are termed as unclassified or 
undifferentiated ALL. 
They concluded that  most cases of ALL expressing myeloid markers not fulfilling the 
diagnostic  requirements  of  biphenotypic  leukemia   have  been  found  to  have  prognostic 
features similar to those that do not express myeloid antigens. Mixed lineage acute leukemias 
are cases which have two different population of cells, as MPO positive blasts in an otherwise 
morphologically and immunophenotypically typical ALL.
T cell ALL are subclassified into different stages corresponding to normal thymocyte 
development , the early subtype is negative for surface CD3  and is either double positive or 
double negative for CD4 and CD8 , the later subtype is surface CD3+and positive for CD4 or 
CD8  and  not  both.  Recent  studies  do  not  find  any  prognostic  differences  in  this  sub 
classification of T cell ALL.
It has been concluded that   evaluation of the cytochemical profile in connection with 
immunophenotype helps to classify the AML patients to relevant subtypes with more accuracy.
Myeloid associated antigens are identified in 45.6% of pre B cell ALL and in 32% of T 
cell ALL. , CD13 and CD33 are commonly associated myeloid antigens; these are designated 
as M y + ALL.
Elghetany MT etal had concluded that all cases of acute leukemia are easily subtyped by 
morphology and cytochemistry. Immunophenotyping, karyotyping, and molecular analysis of 
DNA and RNA of leukemia cells may be required to define cell lineage. Lineage assignment is 
based on the 
1) morphological features 
2) cytochemistry and
3) immunophenotyping
CYTOGENETICS
Leukemias  are  associated  with  changes  in  chromosome  number,  translocation  and 
inversions of genetic material. These are associated with activation or increased transcription of 
oncogenes. Cytogenetics is important in diagnosing, identifying prognostic groups, monitoring 
progression of disease such as MRD and is integral in WHO classification.
MOLECULAR GENETICS
It is a recent technology that allows analysis of molecular genetics in leukemias. PCR 
and southern blot techniques are used to study genetic alterations. Genetic profiling of specific 
leukemia is further expanded by micro array analysis. Molecular genetics is used to identify 
immunoglobulin in B cells and TCR gene rearrangement and in recent past to study bcr /abl 
translocation and translocation 15; 17. 
Molecular  studies  are  advantageous  in  that  they  detect  very  few  populations  of 
malignant cells (as few as 1 – 5 % of cells in a sample) and can also lead to more rapid test 
completion.
Congenital leukemia: It is strictly defined when diagnosed between birth and 4 weeks 
of age. AML ranges from 50% to 90% in various studies.
Genomic  instability  is  suggested  in  a  few  cases  of  congenital  leukemia  that  show 
multiple  immunoglobulin  heavy  chains  by  recombinant  DNA  technology.  Clinical 
manifestations of congenital leukemia differ in varying degrees from older infants and have 
nodular skin lesion.
CLASSIFICATION
Acute leukemias are phenotypically classified on the basis of retained partial capacity of 
differentiation, they are basically classified into 
1) Myeloid ( non lymphocytic ) and
2) Lymphoid 
As per the pediatric clinics of North America, morphologic features and cytochemical 
staining of blast cells are usually sufficient to distinguish ALL from AML but they do not 
establish the immunologic subtype of cells, a necessary consideration in the comprehensive 
diagnosis. .
FAB CLASSIFICATION OF AML 
             The morphologic approach to AML culminated in the development of standard criteria 
beginning  in  1976 by  the  French/American/British (FAB) working group,  in  what  became 
known as the FAB classification of AML.
 Daniel etal had proposed revised criteria for classification of AML .It is based primarily 
on morphologic cytochemical and immunophenotypic features of blast cells.
 Argyle JC etal  quoted the weakness of the FAB classification which includes60.
1) Interobserver variability, 
2) The failure to incorporate cytogenic data into diagnosis, and
3)  Poor correlation with clinical outcome
 Modification of the FAB classification was made with recognition of new morphologic 
subsets of AML and it included immunologic confirmation of M0 and M7 subclasses.
M0 - Minimally differentiated AML
Large  agranular  Blasts  that  lack  definite  cytological  and  cytochemical  markers  of 
myeloblasts  there  is  often  a  stem cell  pattern  of  antigen  expression,  with  CD34  and  Tdt 
positivity.
Incidence is 2 -3% of AML cases61.
The criteria for Diagnosis  of M0 requires less than 3% of MPO-Positive and sudan 
black –B+ve cells but more than 20% of leukemia cells expressing myeloid antigens CD13, 33, 
and 11762. It is also found that lymphoid associated antigens CD2, CD7, CD19 may also be 
expressed in AML M0.
M1 - AML without differentiation 
Incidence is 10- 20% cases of AML63. It is more common in adults, with median age of 
45-50 years64. 
Blasts are more than 90% and more than 3% of blasts are peroxidase positive; few blasts 
show Auer rods and little maturation beyond the myeloblast stage.
M2 - AML with maturation
First described in 1973.   Its  incidence is 30%. It  is  commonly seen in children and 
young adults.Between 5 and 12% of all AML Patients have the t(8;21). Immunophenotypic 
markers include the presence of myeloid antigens, increased expression of the natural killer cell 
associated antigen CD56, and less commonly, the B cell antigen CD1965,66.
 t (8;21) may be predicted by typical morphology, including prominent auer rods, auer 
rods in maturing neutrophils, marrow eosinophilia with  salmon colored granules, cytoplasmic 
globules and vacuoles, abnormal secondary granules that partially obscure the nucleus, giant 
granules, rim of peripheral cytoplasmic basophilia, and bilobed  neutrophils67.
M3 - Acute promyelocytic leukemia
Incidence is 5-10%68. Most patients are younger, mean age 30 to 38 years. 
The morphologic features of M3 blasts are, nuclei of most cells are bilobed or reniform; 
hyper granular abnormal promyelocytes with bundles of auer rods are present. Confusion with 
an atypical monocytic leukemia is frequent; M3v variant is characterized by deeply notched 
nucleus with few fine granules and infrequent Auer rods.
The myeloid antigens CD13 and CD33 are present but HLA DR is absent; the micro 
granular variant commonly expresses CD34 and the T cell antigen CD269.
M4 - Acute myelomonocytic leukemia
Incidence is 16-25%, with a median age of 40 to 45 years. Myelocytic and monocytic 
differentiation  is evident , 20%-80% of non erythroid cells are monoblastic, myeloid elements 
show range of  maturation,  M4EO variant  is  associated with >5% dysplastic  eosinophils  in 
marrow70.
Monoblasts  are  positive  for  nonspecific  esterase.  When  stained  with  PAS,  the 
eosinophilic granules themselves are positive, whereas normal eosinophils demonstrate only 
inter granular staining.
M5 - Acute monocytic leukemia 
Incidence is 10 %. In M5a subtype, monoblasts predominate in marrow and blood; in 
M5b subtype, mature monocytes predominate in the peripheral blood71. 
Patients with M5a tend to be younger (75% < 25 years of age) than those of M5b, but 
both include a wide age range.
Ultra  structural  studies  are  helpful  to  differentiate  pure  monocytic  form  from  the 
myelomonocytic variety It shows that monoblasts and more mature monocytoid forms have an 
extreme nuclear irregularity frequent nuclear bridges and blebs and abundant cytoplasm with 
many dense granules, pinocytic vesicles and vacuoles.
 Elevated  levels  of  lysozyme are  found in  more  than  two-third  of  patients  and  may 
contribute to renal insufficiency or proteinuria .      
M6 - Acute erythroleukemia 
Dysplastic  erythroid  precursors  (some  megaloblastoid,  others  with  giant  or  multiple 
nuclei) predominate, and within the non erythroid cells >30% are myeloblasts
Erythorleukemia usually occurs in patients of 50 yrs  age or older and is more common in 
men .
The  presenting  complaints  are  constitutional,  including  fatigue,  malaise,  and  other 
complaints related to anemia, but in approximately one-third of patients, bone pain may be a 
major symptom. 
In some cases of M6, the erythroid cells may show strong cytoplasmic PAS positivity. 
This is granular in early erythroid precursors and diffuse in later stages. Erythroid precursors 
are PAS negative in normal individuals and in most of the diseases, including megaloblastic 
anaemia. They are sometimes positive, however in iron deficiency anemia, thalassemia, and 
refractory anaemia with ring sideroblasts.
M7 - Acute megakaryocytic leukemia 
AMgL was added to the FAB classification in 1985. It represents 5-10% of cases of 
AML72.
Megakaryoblasts  react  with platelet  specific  antibodies directed against  GPIIb/llla  or 
VWF;  Serum lactate dehydrogenase levels are often elevated with osteosclerotic and osteolytic 
lesions being demonstrated radiographically.
Myelofibrosis  or  increased  marrow reticulin  are  seen  in  most  cases.  Cytopenias  are 
usually present, but approximately 30% of patients have platelet counts that exceed 1,00,000/ 
cu.mm73.
WHO  classification  recognizes  chronic  eosinophilic  leukemia  with  the  overlapping 
hypereosinophilic  syndrome  and  acute  basophilic  leukemia  and  the  spectrum of  mast  cell 
disease including mast cell leukemia
WHO CLASSIFICATION OF AML 
AML with recurrent cytogenetic abnormalities 
It has a flat incidence through out life with median age in 30s .They constitute 85% of 
patients with AML in young patients and a meagre percent of elderly patients. AML with t (8; 
21) (q22; q22) (AML1/ETO), constitute 10% to 15% of cases of AML and exhibits FAB M2 
morphology.
AML with inv (16) (p13;q22) or t(16,6) (p13;q22) (CBFb/MYH11), constitutes 6 to 8% 
of AML cases. It is associated with FAB M4Eo morphology
Acute  promyelocytic  leukemia  [AML  with  t(15;17)  (q22;12),  (PML/RAR-a)  and 
variants. It constitutes 8-10% of AML cases. There is a high correlation with M3h or M3v 
morphology. 2 to 3% cases have M1 or M2 morphology.
AML with 11q23 (MLL) abnormalities. It is associated with FAB M5 morphology. It 
represents 5-8% of cases.
AML with multilineage dysplasia 
Myelodysplastic syndrome (MDS) type dysplastic features should be present in at least 
2 cell lines  
AML and myelodysplasia syndrome, therapy-related 
Alkylating agent-related 
Topoisomerase II inhibitor-related
AML not otherwise categorized 
            AML minimally differentiated
AML without maturation
Acute myelomonocytic leukemia 
Acute monocytic leukemia
Acute erythroid leukemia 
Acute megakaryocytic leukemia 
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma 
Acute leukemia of ambiguous lineage 
Biphenotypic acute leukemia 
Undifferentiated leukemia.   
Categories  of  AML  with  recurrent  cytogenetic  abnormalities  of  t(15;17),  t(8;21), 
inv(16)/t(16;16), and 11q23 showed significant differences in 5-year survival. No significant 
difference was identified between AMLs arising from myelodysplasia and de novo AML with 
multilineage dysplasia, but all cases with multilineage dysplasia had a worse survival than all 
other AML and other AML without favourable cytogenetics. FAB types M0, M3, and M4Eo 
showed  differences  in  survival  compared  with  all  other  FAB  types,  with  M0  showing  a 
significant association with high-risk cytogenetics and 11q23 abnormalities. Other FAB groups 
and WHO AML, not otherwise categorized subgroups did not show survival differences 
Multiparameter  analyses,  including  immunological  and  ultrastructural  assays,  were 
important in arriving at the appropriate diagnosis of acute leukemia of ambiguous lineage in the 
new WHO classification.
FAB CLASSIFICATION OF ALL
FAB in 1976 classifies acute lymphoblastic leukemia (ALL) into three types based on 
morphology as ALL L1, L2, and L3 as described before.
FAB classification of ALL has got no prognostic significance.
L1&  L2  morphological  types  bear  no  relationship  to  immunological  type  or  other 
prognostic factors.
             Loffler H et al had noted that the identification of the L3 variant is of major 
importance.  .  According  to  studies  there  is  a  high  but  not  universal  correlation  of  the  L3 
phenotype as defined by morphology with the immunologically defined B-ALL with surface 
expression of immunoglobulins.13  
            The prognostic significance of being able to distinguish between L1 & L2 morphologic 
subtypes has never been fully proven. Findings with established prognostic significance, such 
as  favourable  and  unfavourable  cytogenetic  alterations  occur  in  both  L1  & L2  .Similarly 
immunophenotypes that may be of prognostic significance do not correlate well with L1 & L2 
morphology74.  
It has been proposed in the recent WHO classification scheme that the L1 & L2 groups 
should be combined and designated ALL of L1 and L275.
In contrast with T-cell ALL, lymphoblastic lymphomas of the precursor T-cell lineage 
usually have no or a minimal peripheral blood or bone marrow involvement and have normal or 
minimally decreased levels of hemoglobin, white blood cells, and the platelets76. 
Arbitrary criteria such as the presence of the more than 25% blasts in the bone marrow 
also have been used to distinguish ALL from lymphoblastic lymphomas77. 
      Lymphoblast lymphomas and ALL have more similarities than differences in pathology, 
immunophenotype, and genotypes and hence they have been regarded as process falling within 
the spectrum of a single disease entity. ALL and lymphoblast lymphomas are grouped under 
the  category  labeled  lymphoblastic  leukemia  /  lymphoma  in  the  Revised  European  and 
American Classification of  Lymphoid Neoplasm’s  (REAL) and in  the  WHO Classification 
Scheme
           PAS (Periodic Acid Schiff) negativity and focal AP (acid phosphatase) positivity, as 
well as white blood cell count and serum lactic dehydrogenase levels, were significantly related 
to T-ALL when compared with B-ALL, on the contrary, no statistically significant difference 
was demonstrated in the clinical outcome.
Hoelzer D et al in their analysis concluded that there are some serious pitfalls of the 
morphology  in  T-ALL,  clearly  indicating  the  need  for  immunological  analysis  of  the 
leukaemic  cells.  However,  morphology  remains  an  essential  component  of  the  diagnostic 
repertoire,  especially when the marrow is difficult  to aspirate and in cases with equivocal 
immunological  findings.  Furthermore,  recognition  of  a  separate  myeloid  leukaemic 
component in addition to the lymphatic one requires a morphological analysis.
Despite  the  advent  of  modern  ancillary  techniques  for  ALL  diagnostic  evaluation, 
morphologic examination and cytochemical staining of well-prepared air-dried bone marrow 
and peripheral blood smears are critical in the pathologic diagnosis and classification of acute 
leukemias.
          An important aspect for the FAB classification of acute leukemia is the cytochemical 
reactivity  pattern  of  the  blasts,  Unlike  acute  myelogenous  leukemia  (AML),  no  single 
cytochemical test is specific for ALL, ALL is negative for myeloperoxidase in cytochemistry 
studies  and  lacks  staining  for  the  myeloperoxidase  protein.  Occasionally  the  morphologic 
distinction between L1/L2 and L3 may be obscured because L1/L2 blasts may sometimes show 
significant cytoplasm vacuoles. 
The WHO classification does not group the ALL together, but separates them under 
three broader categories of lymphoid disease:
1. Precursor B cell 
2. Precursor T cell
3. Mature B cell neoplasms   
In  each  case  it  clumps  predominantly  leukemic  disease  with  predominantly 
lymphomatous disease based on similar biologic and genetic characteristic of disease rather 
than clinical presentation.   
The term biclonal  or  bilineage leukemia is  used to  indicate  a  disorder  that  has  two 
distinct leukemic cell populations One that usually marks with myeloid markers and the other 
with lymphoid markers.
PROGNOSTIC FACTORS & RISK ASSESSMENT:
ALL:
Favourable risk factors include female sex, age 1 to 9 years, WBC count less than 5,00 
cells per cumm, LI morphology, and hyperdiploidy.
Adverse factors include : male sex, age less than 1 year and more than 9 years, count 
more  than  50,000  cells  per  cumm,  L3  morphology,  CNS  disease,  mediastinal  mass, 
hypoploidy, Philadelphia chromosome and t(4;11), blast on day 7 or 14 after start of therapy. 
Advanced age and high  WBC count  at  the  time of  diagnosis  have  a  significantly  adverse 
prognosis. Unfavourable cytogenetic abnormalities in adult ALL include t(9;22), t (4 ;11) and 
q21;.78          T cell ALL is a favourable prognostic factor.
AML:
 Favourable factors include t(8;21,t(15;17),inv16.
Adverse  factors:  Secondary  AML  or  MDS,  monosomy  7,  extra-medullary 
leukemia,WBC count of more than 100,000 cells per cumm79.
RELAPSE:
               25% of children with ALL relapse after treatment. The main sites of treatment are 
bonemarrow, CNS, and the testes. Features of relapse are a morphological shift from small L1 
blasts to larger pleomorphic L2 to L3 blasts, additional changes in cytogenetics occurs in 10% 
of cases80.
SURVIVAL AND PROGNOSIS:
            The prognosis in ALL has improved from less than 5% survival before 1965 to 
25%-50% during the 70s to 70% during the 80s and 80% for children in the 1990s. In AML the 
long term survival has increased from 10 to 40%81.
MATERIAL & METHODS
The present study was carried out in the Department of Pathology, Madurai Medical 
College, Madurai between Jan 2005 and Jan 2007.
All patients with acute leukemia who were admitted in the Departments of Pediatrics, 
Medicine & Medical Oncology at Government Rajaji Hospital, Madurai were included in this 
study.
The clinical and lab profiles were evaluated and were classified into AML/ALL using 
FAB classification. The results of 121 patients are presented in the study.
A thorough history concentrating on specific  epidemiological pattern, family history, 
environmental  and  previous  chemotherapy  were  taken into  account.  This  was  followed  by 
detailed physical  examination.  On suspicion of  leukemia the  following investigations  were 
performed.  Hb,  TC,  Ultrasound Abdomen,  Peripheral  smear,  Bone  marrow aspiration,  and 
special studies like PAS & MPO for all cases. Immunophenotyping and karyotyping were done 
in selected cases.
Sample collection & processing:
For all patients smears were prepared and air dried and stained by Leishman stain. The 
blasts  were  categorized  into  myeloblast  or  lymphoblast  depending  on  morphology. 
Cytochemical staining were done within 24 hours (Annexure II) and they were classified into 
AML or ALL depending on the staining pattern. Cases that were PAS and MPO negative were 
analyzed by flow cytometry using panel of markers.
DATA ANALYSIS:
The information collected regarding all the selected cases were recorded in a Master 
Chart. Data analysis was done with the help of computer using Epidemiological Information 
Package (EPI 2002). Using this software, frequencies, percentage, mean, standard deviation, x2 
and  'p'  values  were  calculated.  A  'p'  value  less  than  0.05  is  taken  to  denote  significant 
relationship.
Sensitivity and specificity were calculated using the following formulae. 
Sensitivity =            True positive                     x 100
True positive + False negative
Specificity =             True negative                     x 100
False positive + True negative
Accuracy =  True positive + True Negative x 100
              No. of cases 
OBSERVATION AND RESULTS
In the study period from June 2005 to January 2007, 2921 peripheral smear materials 
were received from Government Rajaji Hospital Madurai. Of these, acute leukemia accounted 
for 121 cases. Out of these 121 cases, 76 were ALL, 44 were AML, and 1 was biphenotypic 
leukemia (others).
The  overall  incidence  of  ALL was 62.8%,  AML – 36.4% and that  of  biphenotypic 
leukemia was 0.80%.
Among  ALL,  ALL-L2  accounted  for  60.5%  of  cases  followed  by  ALL-L1  which 
accounted for 39.5% of cases. ALL L3 was not encountered in this study. In children L1 and 
L2 accounted for 50% cases of ALL. In adults,     ALL L2 accounted for 75 % and ALL L1 
accounted for 25 % of cases        (Table 1).
In AML, 59.1% of cases were of AML M2 and 18.2 % of cases were of AML M4 type. 
AML M5 accounted for 11.3 % of cases.9.1 % of cases were AML M1 (Table – 1).
AGE:
In children, 57.4% of leukemia cases occurred between 6-12 years age group. The mean 
age was 6.2 years in children. (Table – 2). 
In patients above 13 years of age, 44.8% of cases occurred between 13 and 20 years; 
25.4% occurred between 21and 30 years. The mean age group in adults is 27.6 years. (Table – 
2)
In children, ALL accounted for 79.6% of the cases and AML accounted for 16.6% (L1 
& L2). (Table-1) 
In adults, the most common leukemia was AML (52.3%) followed by ALL (47.7%). In 
ALL  the  difference  in  incidence  of  different  types  of  leukemia  in  children  and  adults  is 
statistically significant ( p value- 0.0001). 
SEX: 
Out of the 121 cases studied, 83 cases were male and 38 were female. The male female 
ratio was 2.1:1 (Table – 3).
PRESENTING SYMPTOMS:
Out of 121 cases, 99 cases presented with fever and 25 cases presented with bleeding. 
Fatigue was present in 27 cases (Table – 4).  Two cases of AML presented with proptosis. 
(Figure  -1).  There  was  no  statistically  significant  difference  in  the  presenting  symptoms 
between AML & ALL (p value 0.42).  
CLINICAL FEATURES:
Anaemia was present in 85 cases of acute leukemia. Generalized lymphadenopathy was 
present in 35 cases, of which 28 cases were ALL and 7 cases were AML. Testicular mass was 
present in 1 case of ALL. FNAC of the mass revealed a hypercellular smear with sheets of 
atypical lymphoblasts in a haemorrhagic background. (Figure – 2). 
Table – 5 shows the various clinical features in different types of leukemia.     
Gingival hyperplasia was seen in 5 cases of AML and in 1 case of ALL. (Figure – 3)
A 13 year old boy with AML presented with multiple congenital abnormalities such as 
growth retardation, cardiac defects and absent radius (Figure – 4). 
Laboratory Findings 
Hemoglobin (Hb)
34% of cases of leukemia had Hb level less than 5 gm/dl. 56% of cases of leukemia had 
Hb levels between 5-10 gm/dl. 10% of cases had counts more than 10gms/dl (Table – 6).
The mean Hemoglobin was 6.26 and 6.56 for ALL and AML respectively.
There was no statistically significant difference in Hb % between AML and ALL cases. 
TOTAL COUNT (TC):
5.7% of cases had a total count of less than 10,000. 57.8% of patients had a TC between 
10,001- 20,000. 
Mean total count at presentation was around 39,000 for acute leukemia cases. There was 
a statistically significant difference of mean total count in AML and ALL. AML is associated 
with higher total count. (p value 0.012.)
Hyperleucocytosis was present in 8.3% of cases (Table – 7). Figure – 5 shows peripheral 
smear of an ALL patient with clinical features of leucostasis. The total count of the patient was 
above 1, 00,000/cumm.    
PLATELET COUNT:
11.7% of leukemia cases showed platelet count below 25,000 cells/cumm.
A normal platelet count of more than 1, 50,000 cells/cumm was seen in 21.6% of cases 
of acute leukemia.
Mean platelet count was around 96,283 for ALL and that for AML was 1, 00,116. This 
difference was statistically insignificant (Table – 8).
PERIPHERAL SMEAR:
14.2% of patients had a blast count of less than 20%, of which 88% were ALL and 12% 
were AML. Blast in peripheral smear ranging from 20-89% was seen in 67.5% of cases and a 
blast count of above 90% was seen in 18.3% of cases. 
The average percentage of blast in peripheral smear was 60.44%
The mean blast percentage was 68.28 and 56.14 for AML and ALL respectively. 
There was no statistically  significant difference in percentage of  blasts  in AML and 
ALL. (Table – 9) 
BONE MARROW:
64.2% of cases of acute leukemia had more than 90% blast in bone marrow 35.8% of 
cases had blast count between 20% and 89%. There was no statistically significant difference in 
percentage of blast between ALL and AML. (Table – 10) Figure – 6 shows the low power view 
of  hypercellular  marrow  with  absent  fat  cells  with  suppressed  megakaryopoiesis  and 
erythropoiesis. The mean percentage of blast in bone marrow was 80.81 and 84.15 for AML 
and ALL respectively.       
MORPHOLOGY:
Out of the 121 cases studied morphologically, 63 cases resembled lymphoblast and 58 
cases resembled myeloblast. The Myeloblast showed increased nuclear cytoplasmic ratio with 
fine chromatin, 2 – 5 distinct nucleoli and cytoplasmic granules (Figure – 7). Auer rods were 
more  prominent  in  AML  M2  than  in  AML  M1  (Figure  –  8).  A  case  of  AML  M3  was 
encountered, it showed abnormal promyelocyte with dense granules & faggots in the cytoplasm 
(Figure – 9). Monoblastic differentiation was observed in AML M4 and AML M5 types. M4 
showed myeloblast  of  20-80% (Figure  – 10).  AML M5 showed   >  80% monoblast  with 
centrally placed nucleus, pale cytoplasmic vacuolization and perinuclear clearing (Figure – 11). 
Among the blast which were diagnosed morphologically as lymphoblast 73% were ALL 
and 25.4% turned out to be AML after cytochemical and immunophenotyping techniques (one 
case  was  biphenotypic  leukemia).  Lymphoblast  showed  eccentric  nucleus  with  cleaved 
indended to regular nuclear membrane, coarse chromatin and indistinct nucleoli. ALL L1 blast 
were predominantly small cells with scant cytoplasm and coarse chromatin (Figure – 12). ALL 
L2  blast  were  composed  of  large  heterogenous  cells  with  moderate  amount  of  cytoplasm 
(Figure – 13). Occasional L2 blast showed dense granules in cytoplasm (Figure – 14). 
Out of the 58 myeloblasts, 51.7% of cases turned out to be ALL and 48.3% of cases 
were AML. 
 The accuracy of diagnosing ALL on morphology alone was 61.2% and that of AML on 
morphology alone was 39.5%. (Table – 11)
CYTOCHEMISTRY:
MPO:
Out of 121 smears stained with MPO, positivity was present in 39 cases. Myeloblast 
showed dense granular brownish black cytoplasmic positivity (Figure – 15). Auer rods were 
prominently seen after MPO staining. Intense cytoplasmic staining was observed in AML M3 
(Figure – 16). Negative staining was observed in ALL (Figure – 17).          
In cases of AML, 88.6% were MPO positive and 11.4% were MPO negative.
The sensitivity, specificity and accuracy of MPO in classifying AML was 89%, 100% 
and 95.9% respectively. (Table – 12)  
SUDAN BLACK B:
Out  of  121  smears  stained  with  SBB,  positivity  was  present  in  41  cases.  A  dense 
smudgy blackish cytoplasmic staining was seen in AML cases      (Figure – 18).  Intense 
staining was seen in AML M3 compared with other sub types (Figure – 19).     
In SBB positive cases 92.85 % were AML. 6.25 % of SBB negative cases were AML. 
The sensitivity, specificity and accuracy of SBB in classifying AML was 89%, 97% and 93.4% 
respectively. (Table – 13) 
PAS:
PAS positivity was present in 76 cases of acute leukemia. PAS positivity is shown by 
block staining pattern (Figure – 20). 
Out of the 76 cases which are positive for PAS, 66 were ALL and 10 cases turned out to 
be AML after further studies.
The blasts in 45 cases were negative for PAS. True negative were 35 cases and false 
negative was 10 cases.
In cases of ALL 86.8% showed block positivity, and 13.2% of cases were negative for 
PAS. 
In cases of AML, 77.3% were negative for PAS and 22.7% were block positive for PAS. 
(Table -14)
The sensitivity, specificity and accuracy of PAS in our study was 73%, 78% and 83.5% 
respectively.
The sensitivity, specificity and accuracy of various stains are given in Table - 15.
IMMUNOPHENOTYPING:
Immunophenotyping  was  done  in  15  cases.  The  cases  which  were  MPO and  PAS 
negative were analyzed immunohistochemically. Out of 15 cytochemically inconclusive cases, 
10 were positive for lymphoid markers and turned out to be ALL and 5 were positive for 
myeloid markers and turned out to be AML.
A 2 years old boy with hepatosplenomegaly had blasts that morphologically resembled 
monoblasts. MPO and PAS were negative in that case. Morphological diagnosis of AML M5 
was made. Immunophenotyping revealed the blasts to be positive for pre B cell markers.
A 10 years old female child had blasts that morphologically resembled lymphoblasts, 
MPO was negative, immunophenotyping revealed it to be Biphenotypic leukemia.
The most common CD markers positive in ALL cases were CD 10 and CD 34.
CD 33 and CD 14 were positive in AML cases.
CYTOGENETICS:
A 10 year old female child presented with massive splenomegaly, hyperleucocytosis and 
35% blasts in peripheral smear. Mature and maturing forms of myeloid series were present in 
PS and Bone marrow. A diagnosis of childhood CML was made .Cytogenetic studies in this 
case  was  negative  for  Philadelphia  chromosome.  No  other  chromosomal  anomalies  were 
present .It was classified as AML not other wise specified as per WHO classification.
DISCUSSION
In the present study the incidence of leukemia in Madurai is 0.45% which is comparable 
with Indian studies quoting an incidence of 0.34% to 1%8.
The most common type of acute leukemia in the present study is ALL (62.8%) followed 
by AML (36.4%) which is comparable with the observations of Kapoore. G in whose study 
ALL composed 62.03% of cases and AML 37.9% of cases9.
In the present study 56.6% of cases of ALL is seen in children and 80% of cases of 
AML are seen in adults.  
In children the incidence of ALL L1 and ALL L2 is equal. In adults L2 morphology is 
more common accounting for 75% of ALL cases .This is similar to the study conducted by 
Loffler H et al13 in which L2 was common (68%). The comparative study of morphological 
distribution of ALL in children and adults is given in the table 16 and 17 respectively.
In the present study AML M2 is most common, accounting for 59.1% of AML cases 
followed by M4 which accounts for 18.2% of cases. The incidence of M5 is 11.3%. This is 
comparable with those quoted by David H in his study on Acute myelogenous leukemia14 in 
which the most common leukemia was AML M2 followed by M4 and M5. AML M0 was not 
encountered in this study.     
AGE INCIDENCE:
In the present study the most common type of childhood acute leukemia is ALL (79.6%) 
followed by AML (16.6%). Table 18 compares the incidence of AML and ALL in children in 
present study with that of Manipur study and Western literature8, 11.
In the present study incidence of infantile leukemia is 11.1%. ALL constituted 66% and 
AML 44% of infantile leukemia cases. This is similar to the study conducted by Somgee etal at 
the Department of Medical Oncology TATA Memorial Hospital Mumbai16. Western literature 
quotes AML M5 M4 to be more common15.
In adults, the most common type of leukemia is AML constituting 52.3% of cases .The 
AML: ALL ratios is 2.57:1 while other reviews quote a ratio of 4:113.
SEX: 
In the present study both types of leukemia is more common in males. The male female 
ratio is 2.5: 1. This ratio is higher than that quoted by Singh et al (1.5:1) in his study13.
ETIOLOGY:
There is no identifiable risk factor for ALL in this study. 7% of cases of AML had a 
definite  etiology.  2 cases were associated with congenital  disorder  and 1 case was therapy 
related AML.
As per literature in patients with Down’s syndrome, AML is more common in children 
less than 3 years of age and in neonatal period it may present as congenital leukemia or as 
Transient  myeloproliferative  disorder  (TMD).  Both  cases  have  similar  clinical  feature  and 
similar  blast  percentage  and  are  differentiated  only  by  follow  up.  TMD  cases  resolves 
spontaneously while congenital leukemia has a fatal outcome21.
In our study, we encountered a 25 days old child with Down’s syndrome with 35% blast 
in PS and 50% blast in BM.The blasts were of myeloid morphology. Unfortunately we lost 
follow up of the case.
A 13 years  old  boy  with  AML M4 morphology  presented  with  multiple  congenital 
anomalies, dysmorphic features, absent radius and growth retardation. In literature there are 
studies which relate syndromes such as TAR syndrome with AML19.  These syndromes are 
associated with increased risk of mutations.
A 40 years female operated for liposarcoma and on chemotherapy with methotrexate for 
the  past  4  years  developed  therapy  related  AML.  As  per  literature,  leukemia  onset  after 
alkylating agent exposure ranged from 1to 28 years and is most common in 5-9 years range23. 
They have worse prognosis.
PRESENTING SYMPTOMS:
The most common complaint  in 80% of cases in present study is fever followed by 
bleeding. This is comparable to that of Singh etal study8. 
There is no statistically significant difference in presenting symptoms between AML 
and ALL (p value 0.42).
CLINICAL FEATURES 
Generalized lymphadenopathy is present in 28 cases of ALL and only 7 cases of AML. 
This is comparable with studies conducted by Poplack DG in which he concluded that GLP is 
more commonly associated with ALL than with AML.30
In the present study 4.9% of cases has gingival hypertrophy of which 83.6% are AML. It 
is more commonly encountered in AML M4/AMLM5. It is due to infiltration of gingival tissue 
by  leukemic  blasts.  As  per  literature  3-5%  of  acute  leukemia  patients  develop  gingival 
hyperplasia  of  which 88.9% are  AML31.  The various  clinical  features  in  different  types  of 
leukemia is statistically insignificant (p value 0.32). 
LABORATORY FEATURES:
In the present study subleukemic presentation, in which abnormal cells are present in 
peripheral  blood,  but  the  total  leukocyte  count  is  not  elevated  is  seen  in  7  cases  of  acute 
leukemia.  Boggs  DR  in  a  10  year  study  found  53  of  322  cases  to  have  a  subleukemic 
presentation25. 
In  the present study Hyperleucocytosis  was present in 8.3% of cases.  Patient’s  with 
hyperleucocytosis can present with leucostasis with sludging of leukemic cells in capillaries of 
lungs and brain.   
In the present study a normal platelet count is seen in 21.6 % of cases. Rest of them is 
associated with thrombocytopenia, with 11.7% of cases having a platelet count below 25,000. 
Marrow infiltration and chemotherapy are the most common causes of thrombocytopenia in 
acute leukemia cases25.  
In the present study a blast count of less than 20% in PS is seen in 14.2% of cases of 
acute leukemia of these 88.2% are ALL and only 11.8% are AML. In all  these cases bone 
marrow is required for confirmation and typing of leukemia. This is in concordance with the 
observation made by Bennet etal who concluded that first in the sequence of diagnosis of acute 
leukemia is  the distinction from other neoplastic  and reactive diseases and confirmation of 
acute leukemia by morphological and cytochemical studies62.
MORPHOLOGY:
In the present study the blasts in 63 cases resembled morphologically lymphoblast with 
false negativity of 30 and false positivity of 17. The false positivity may be due to monoblasts 
and myelomonoblasts which have clefted nuclei and somewhat condensed chromatin.  False 
negativity may be due to the presence of granules in lymphoblasts (Figure – 14) and presence 
of occasional   3 -5 nucleoli in ALL L2 blasts (Figure – 13).
58 cases in the present study morphologically resembled myeloblast. True positive are 
28 cases. Out of the 28 cases monoblastic differentiation is seen. (Figure – 11). 
In the present study 34% of cases of AML have auer rods, which are reddish rod like 
filaments  of  aggregated  lysozymes  which  are  derived  from  incorporation  of  primary 
azurophilic granules into autophagic vacuoles. These are present in 50% of cases of AML as 
quoted by Ritter J etal79.  He considered them to be pathognomonic of AML. Other studies 
quote an incidence of 15 %63.
The sensitivity,  specificity  and accuracy of  morphology in diagnosing ALL is  61%, 
62.2% and 61.2% respectively and the accuracy of morphology in diagnosing AML is 39.5%.
As per the studies conducted by Bennett etal, even experienced morphologists were able 
to  classify  only  70%  of  cases.  Correlation  with  morphology  is  poor  because  it  is  more 
subjective given to observer variation, and is based on qualitative factors. 
MPO:
In the present study the sensitivity, specificity and accuracy of MPO in diagnosing AML 
is 89%, 100% and 95.9% respectively as compared with the study conducted by Cheng etal in 
2005 who quoted a sensitivity of 69% and specificity of 100%47. False negativity is commonly 
associated with AML M5 morphology. These monoblasts are negative for MPO and positive 
for NSE.
As per the work done by Yang O, a MPO positivity of > 3% confirms myeloid lineage 
hence in almost all  cases distinguishing AML from ALL is  relatively easy by staining for 
MPO.  However  AML  M0  M5  and  M7  may  be  negative  for  MPO  for  which 
immunophenotyping is essential82.  
Biphenotypic leukemia is MPO negative. As per the studies conducted by Raymond Lay 
etal in cases of biphenotypic leukemia more than 3% MPO positive blasts can occur58.
PAS:
Out of 121 cases studied by PAS stain True positive is 66, false positive is 10, false 
negative is 10 and true negative is 30.
The  sensitivity  of  PAS is  73  % and the  specificity  is  78  %.  Other  studies  quote  a 
sensitivity of 52% and a specificity of 81%53.  The accuracy of PAS in diagnosing ALL is 
83.5% in our study. 
As per  the  work  done  by  Lai  etal  no  single  cytochemical  test  is  specific  for  ALL, 
however it is an integral component in diagnostic evaluation for ALL. Auer rod negative, MPO 
negative,  SBB  negative  and  PAS  positivity  in  a  block  positive  manner  is  of  utility  in 
diagnosing ALL cases58.   
Sudan Black B:
Out of 121 cases studied by Sudan Black B stain false positive is 2 and false negative is 
5. False positivity is due to ALL L2 blast which shows a weak SBB positivity. 
Raymond Lai in his study has confirmed that SBB which stains lipid membrane of MPO 
granule may also show weak positivity in ALL58.  
The sensitivity,  specificity and accuracy of SBB in diagnosing AML cases are 89%, 
97% and 93.4% respectively.
IMMUNOPHENOTYPING:
The lineage of most cases of morphologically and cytochemically poorly differentiated 
acute leukemia can be accurately characterized by immunophenotyping.  
In  the  present  study  13%  of  cases  required  immunophenotyping  for  classification. 
Among them,  10 are  positive  for  lymphoid markers  and turned  out  to  be  ALL and 5  are 
positive for myeloid markers and turned out to be AML.
A 2 years old boy with hepatosplenomegaly with blasts that morphologically resembled 
monoblasts and MPO and PAS negative, diagnosed as AML M5 showed positivity for pre B 
cell markers by immunophenotyping. 
In classification, surface markers are most useful in distinguishing AML and lymphoid 
neoplasms. They are also useful in distinguishing AML M0, AML M5 and AML M7 and in 
defining hybrid and biphenotypic leukemias. As per the extensive work done by Bennett JM 
etal62 in  1991,  surface  markers  in  AML  are  most  appropriate  for  the  evaluation  of 
morphologically and cytochemically atypical or undifferentiated leukemias or suspected hybrid 
leukemias. 
Snower  D.P  etal  in  his  study  stated  that  the  absence  of  blasts  being  positive  for 
peroxidase is not a reliable indicator for the lymphatic nature of a leukaemia, even if the PAS 
reaction  is  typical  for  ALL.  The  morphological  diagnosis  of  ALL needs  confirmation  by 
immunophenotyping in each instance53.t
In the present study the most common CD markers positive in ALL cases are CD 10 
(common lymphoid antigen), CD 34 (precursor antigen) and CD 19 (B cell marker) suggesting 
a precursor B cell ALL. 
In the present study CD 33 (common myeloid antigen) and CD 14 (Monocytoid antigen) 
are positive in AML cases which are MPO negative and SBB negative.
In this study, a 10 years old female child with blasts that morphologically resembled 
lymphoblasts, MPO and PAS are negative, immunophenotyping revealed it to be Biphenotypic 
leukemia. Both myeloid (MPO) and lymphoid (CD 19, CD10) markers are positive 
SUMMARY
The salient features observed in the present study are 
1) In children the most common acute leukemia is found to be ALL.
2) In adults the most common acute leukemia is AML.
3) Males predominate in both types of leukemia.
4) Subleukemic presentation is found in 5.8% of cases.
5) In subclassifing acute leukemia, ALL L2 is more common and AML M2 is found to 
be more common among AML.
6) In the present study morphology alone showed an accuracy of 61.2%.
7)  The percentage of sensitivity, specificity and accuracy are 89%, 100% and 95.9% 
respectively for MPO stain in AML cases.
8) The sensitivity of 73%, specificity of 78% and accuracy of 83.5% is found for PAS 
stain in ALL cases.
9) The cytochemical stains markedly improved the accuracy of identifying AML cases.
10)  Only 13% of cases required Immunophenotyping to classify into AML and ALL.
CONCLUSION
The diagnosis  of  acute  leukemia  entails  a  stepwise  approach. First  in  sequence  and 
importance is  the  distinction of  acute leukemia from other  neoplastic  diseases  and reactive 
disorders. Second is differentiating acute myeloid and acute lymphoblastic leukemia. The third 
facet is the classification of AML and ALL into categories that define treatment and prognostic 
groups.
The  progressive  developments  in  the  diagnosis  of  leukemias  have  unfortunately  not 
translated into reality in the developing world. There exist huge discrepancies in the diagnosis 
of leukemias between developed and developing countries as quoted by Maman Chandey  
Morphology remains the means by which acute leukemia is initially detected and is a 
major aid in distinguishing ALL and AML. 
Cytochemical  reactions  provide  additional  information  with  which  to  distinguish 
between the two distinct acute leukemia entities
With the addition of cytochemistry to the morphologic assessment, most cases of acute 
leukemia can be appropriately designated as either AML or ALL. However, there remains a 
significant minority of cases that cannot be definitely diagnosed by these methods.
In a developing county like India where immunophenotyping are not available for poor 
patients due to socioeconomic constraints, morphology combined with cytochemistry provides 
an improvement in identification. 
In  conclusion  cytochemistry  substantially  improved  the  classification  of  leukemias 
which are very beneficial to the patients of Government Rajaji Hospital, Madurai, regarding the 
line of treatment.
Immunophenotyping  is  essential  in  cases  where  morphology  and  cytochemistry  are 
inconclusive.
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ANNEXURE – I
PROFORMA  
NAME : AGE / SEX :
ADDRESS :
O.P.NO. H. NO
WARD
PRESENTING SYMPTOMS 
Fatigue / Weight loss / Fever / Abnormal Masses / Purpura / Bleeding / Bone and 
joint Pain / Past history /Family history.
CLINICAL FEATURES:
Anemia  /  Lymphadenopathy  /  Hepatomegaly  /  Spleenomegaly  /  Sternal 
Tenderness / Mediastinal Mass/ CNS Involvement / Fundic Haemorhage.
OTHER ORGAN INVOLVEMENT:
LAB FEATURES:
Total Count :
Haemoglobin :
RBC Count :
Platelet Count :
Bleeding Time :
Clotting Time :
PERIPHERAL SMEAR STUDY 
RBC :  Hypochromic / Normochromic / Macrocytic Others 
WBC : Count : Increased / Decreased 
DC : Blasts ; Promyelocyte; Myelocyte; 
Metamyelocyte; Stab; Neutrophil; 
Eosinophill ; Basophil; Lymphocyte ;
Monocyte 
PLATELETS : Increased / Decreased / Normal 
Others :
BONE MARROW:
Site : Sternum / Iliac Crest / Others 
Biopsy / Aspiration 
Cellularity: Normocellular / Hypocellular / 
Hypercellular 
Erythropoiesis: Active / Suppressed 
Maturation: Normoblastic / Micronormoblastic / Megaloblastic.
Leukopoiesis: Active / Suppressed 
Blasts:
Size:
Nucleus:
Location : Central / Eccentric 
Shape : Regular/Cleaved/Indented 
Chromatin : Fine / Course 
Nucleoli : Distinct / Indistinct 
1-2 / 2-5 nucleoli
Nuclear Membrane : Fine / Dense 
 
Cytoplasm : Scanty / Moderate / Plentifull 
Basophilic / Acidophilic / Vacuoles  
Granules / Auer Rods / Others 
Megakaryocytes : Present / Absent 
Plasmacells 
Abnormal Cells 
Myeloid / Erythroid Ratio 
Morphological Blast - Myeloblast / Lymphoblast
CYTOCHEMISTRY 
Myeloperoxidase : Positive / Negative 
PAS : Positive / Negative 
Sudan Black B : Positive / Negative 
Non Specific Esterase:
Immunopheno Typing :
DIAGNOSIS: 
ANNEXURE – II
STAINING TECHNIQUES 
MPO staining Procedure:
Washburn technique: 
Preparation of solution A – 300mg of benzidine and 300 mg of basic fuschin is taken in 
mortal and pestle. A few drops of absolute alcohol is added and made a paste. Then 100ml of 
absolute alcohol is added. In another mortal and pestle 5 gm of sodium nitroprussside crystal is 
taken and distilled water is added drop by drop. This is a saturated solution. Mix both solutions 
and store in amber colored bottle.
Preparation of solution B – hydrogen peroxide.
Staining Methods. 
Fresh air dried smears are taken. Solution A is filtered and poured on the smear. Wait for 
2 – 3 minutes. Then add solution B drop by drop. After 1 min wash it in running tap for 2 mins, 
counter stain with Leishman after fixing the stain in methanol for 2 min.
SUDAN BLACK B STAIN
I. REAGENTS 
1. Fixative: Formal Formalin Vapour (as used in peroxidase stain) 10mts.
2. Sudan Black B Stock Solution:
Sudan Black B powder - 0.3gm
Dissolve in absolute alcohol (ethanol) 100ml
Filter and store in dark bottle at 4 deg C.
      Buffer – Alcoholic phenol Phosphate Buffer
a) Dissolve crystal phenol 16gm in absolute alcohol 30ml
b) Dissolve hydrate disodium hydrogen phosphate (Na2HPO4.12H2O)-0.3gm in 
distilled water 100ml.
Add (b) to (a) – store in dark bottle at 4deg C.
3. Working Sudan Black B Stain
Stock stain 48 ml add Buffer 32ml – Filter.
4. 70% Alcohol.
5. Giemsa stain 1:10 dilution (as for MGG stain).
II. METHOD:
1. Fix smears in formal alcohol for 1 minute. 
2. Wash in tap water very gently (or smear washes off) and air dry.
3. Immerse smears in Sudan Black B working solution in a coplin jar for 45 mins (Keep 
closed to prevent evaporation).
4. Wash in tap water – Shake off excess water.
5. Wash in 70% ethanol for 5 mins.
6. Wash with tap water.
7. Stain with Giemsa stain (in coplin Jar) for 20 mins.
8. Immerse in buffer water pH 6.8 for 10 mins.
9. Rinse in tap water
10. Air dry.
PAS staining procedure:
Air dried films are fixed for 1 min at room temperature in formalin ethanol fixative 
solution and then rinsed for 1 min in running tap water. The slides are then immersed in PAS 
solution  followed  by  rinsing  in  several  changes  of  distilled  water.  This  is  followed  by 
immersion in Schiff reagent. And then wash in running tap water for 5 min. the slides are then 
counterstained with haematoxylin solution. The smears are then examined under microscopy 
for positivity in block pattern.
Karyotyping.
5ml of peripheral blood is taken and the WBC is separated. The WBC suspension is 
incubated at 37 C for three days in a culture media containing phytohaemaggluttinin, which 
stimulates  cell  division.  Colchine  is  added  which  arrests  the  cell  division  in  metaphase. 
Addition of hypotonic solution swells up the cell and disperses the chromosome and makes 
them easy to identify and count. Cells are then spread on a slide, stained with Giemsa and 
photographed  with  a  high  power  microscope.  The  individual  chromosome is  cut  from the 
photograph and the arranged in a orderly manner and the aberrations are noted.

